State Street SPDR S&P Biotech ETF XBI
151.19 USD -5.12 (-3.28%)
At closeNov 12, 2026, 4:00 PM EST
151.20 +0.01 +0.01%
After hours · Nov 12, 4:00 PM ET
150.58 Day range 154.42
111.11 52-week range 169.89
- YTD
- +24.00%
- 1 year
- +32.49%
News
benzinga.com Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? Biotech ETFs face key FDA catalysts as Summit Therapeutics' decision and the Hims-Lilly GLP-1 deal put XLV, IBB and XBI in focus.
fool.com IYH and XBI: Two Distinct Paths to Investing in Healthcare iShares U.S. Healthcare ETF tracks a broad mix of pharmaceutical and medical device companies, while State Street SPDR S&P Biotech ETF focuses strictly on the biotechnology sub-industry. State Street…
fool.com Decoding Healthcare ETFs: Different Sectors, Different Strategies While State Street SPDR S&P Biotech ETF delivered a higher 1-year total return, the Invesco fund has experienced significantly shallower drawdowns and stronger cumulative growth over the past five…
benzinga.com Nasdaq 100 Climbs as Cooler PCE Cuts Rate Hike Bets, Micron Earnings Loom: Stock Market Today Nasdaq 100 gains as softer PCE inflation cools Fed rate-hike bets, with oil above $91 and Micron earnings due after the bell Wednesday.
benzinga.com Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach B. Riley sees 40+ biotech catalysts ahead as rising rates pressure XBI, setting up a key test for the sector during the Q3 2026 earnings season.
benzinga.com Economy Grows 63% in Six Years, 30-Year Treasury Lost Almost As Much Over six years, U.S. nominal GDP rose 63% while the 30-year Treasury fell 60%. Are investors positioned for a surge in stocks and yields?
benzinga.com Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
benzinga.com Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.
benzinga.com What's Going On With Novavax Stock? Shares of Novavax are trading higher Tuesday. The stock is up over 30% over the trailing month as traders weigh updated autumn vaccine authorizations against the company's broader strategic pivot…
benzinga.com Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
benzinga.com Novavax Stock Climbs Monday: What's Going On? Shares of Novavax are trading higher Monday, extending its 30% monthly gains on COVID-19 vaccine approvals and broader biotech strength.
benzinga.com QUICK SPARK: $3.8B SPY Exodus Meets $3.7B QQQ Inflow in One Day QQQ attracted $3.67 billion in ETF inflows while SPY saw $3.82 billion in outflows, as semiconductor ETFs also drew strong investor demand.
benzinga.com Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For MRK, MRNA's cancer vaccine breakthrough could revive the mRNA trade, putting biotech and genomics ETFs back in focus.
benzinga.com Novavax Stock Moves Higher Wednesday: What's Driving the Action? Shares of Novavax Inc (NASDAQ: NVAX) are trading higher Wednesday. The move comes as a major clinical victory in the oncology space generated widespread momentum across vaccine developers.
benzinga.com ‘Never Happened in History,’ Ex-Bridgewater Exec Warns AI Market Is Priced to Perfection Former Bridgewater exec Bob Elliott warns the AI stock rally is an "expectations mania" built on unrealistic growth assumptions.
benzinga.com Here's How Much $100 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth Today State Street SPDR S&P Biotech ETF (NYSE:XBI) has outperformed the market over the past 20 years by 3.16% on an annualized basis producing an average annual return of 12.55%. Currently, State Street…
benzinga.com Bulls Pile Into Moderna As FDA Decision Nears, Ignites 60% Surge In This ETF Moderna shares have surged nearly 30% in five days, ahead of a key FDA advisory vote on its flu vaccine, lifting the leveraged MRNX ETF more than 60%.
benzinga.com Apogee Stock Slides After Blackstone Financing Deal And Positive Drug Data Apogee shares fell after announcing a $1.3 billion Blackstone financing deal alongside positive Phase 2 eczema drug results.
benzinga.com Taiwan Semiconductor, Freeport-McMoRan And More On CNBC's 'Final Trades' Stephen Weiss chose Taiwan Semiconductor as final trade, citing partnership with Applied Materials. Other picks? Freeport-McMoRan.
benzinga.com Moderna's Legal Hit Steals Spotlight From Strong Sales MRNA revenue hits $389M, beating Wall Street estimates. Despite a Q1 loss, Moderna eyes 10% growth and new flu vaccine approvals in 2026.
benzinga.com Tech Leads, Dow Lags As Oil Holds Near $92: What's Moving Markets Wednesday? U.S. stocks were mixed at midday Wednesday as tech stocks rallied while industrials dragged the Dow lower. Oil held above $90 and yields ticked higher, reflecting lingering geopolitical risk.
benzinga.com Citigroup, Morgan Stanley, CBRE Group And More On CNBC's 'Final Trades' Experts predict higher stock prices for CBRE Group and Morgan Stanley, while State Street SPDR S&P Biotech ETF and Citigroup are recommended.
benzinga.com Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfolio. Get the deal details here.
benzinga.com $1000 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth This Much Today 
benzinga.com Biotech ETF With A Twist: Defiance To Donate Initial Advisory Profits To Autism Causes Ahead of April, also the autism acceptance month, Defiance filed for a biopharma ETF with a pledge to donate profits to autism services and research.
benzinga.com BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress BridgeBio Pharma shares Phase 3 trial update, but early data show progress for rare muscle disease treatment.
benzinga.com FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars Moderna's mRNA-1010 flu vaccine clears FDA review, with stock rising ahead of major approvals.
benzinga.com PTC Therapeutics Pulls Translarna Bid After FDA Flags Weak Proof PTC Therapeutics, Inc. (PTCT) stock closed lower following the withdrawal of its New Drug Application for Translarna by the FDA.
benzinga.com Moderna, Mexico Partner To Boost Local Vaccine Production Moderna signs a long-term deal with Mexico to build local mRNA production, transfer technology, and supply up to 10 million COVID vaccine doses for the 2025–2026 campaign.
benzinga.com Novavax Stock Is Surging Monday: What's Driving The Action? Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.
benzinga.com Moderna (MRNA) Stock Pulls Back After Recent Strength Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
benzinga.com Why Your Pneumonia Shot Is About To Get A Massive Upgrade Vaxcyte shares rise after starting Phase 3 trials for its VAX-31 pneumonia vaccine, expanding studies in adults and infants while planning major U.S. manufacturing investments.
benzinga.com Moderna Stock Explodes To New 52-Week High: What's Driving The Action? Moderna Inc (NASDAQ: MRNA) stock is trading higher Thursday morning, hitting a new 52-week high after new cancer trial data.
benzinga.com Equities Surge, Commodities Sink As ETF Investors Streamline Portfolio For 2026 ETF flows show investors piling into equity ETFs while pulling money from commodities, leverage and macro trades as they streamline portfolios for 2026.
benzinga.com As AI Valuations Stretch, Health Care ETFs Step Into The Growth Spotlight Health care ETFs are positioned to benefit this year from weight-loss drug growth and defensive appeal as investors rotate away from AI stocks.
benzinga.com The Year-End 2025 Biotech Rally And What It Means For 2026 
benzinga.com Beyond S&P 500: KKR Flags Asia, Biotech, Infrastructure As Next 'High-Grade' Trades For 2026 KKR's 2026 Outlook finds value beyond the S&P 500. Explore investment strategies in Asia, biotech, and critical infrastructure.
benzinga.com If You Invested $100 In State Street SPDR S&P Biotech ETF Stock 20 Years Ago, You Would Have This Much Today 
benzinga.com Novo Nordisk's Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus Novo Nordisk's FDA-approved weight-loss pill intensifies its rivalry with Eli Lilly, putting health care and biotech ETFs in focus.
benzinga.com Why Is Trinity Biotech Stock Soaring Tuesday? Trinity Biotech (NASDAQ: TRIB) surged on Tuesday due to a large HIV testing order and balance-sheet restructuring.
benzinga.com Uber, Toast And More On CNBC's 'Final Trades' Toast shares rose 2.9% to close at $37.28 on Monday while Uber gained 2.5% to settle at $81.26 during the session.
benzinga.com Eaton, FTAI Aviation And More On CNBC's 'Final Trades' FTAI Aviation (NASDAQ: FTAI) is recommended by investment experts to diversify portfolios beyond tech, while Eaton (NYSE: ETN) and SPDR S&P Biotech ETF (NYSE: XBI) show promising price action. SoFi's…
benzinga.com Apple, Taiwan Semiconductor Manufacturing And More On CNBC's 'Final Trades' Apple will roll out three new iPhone models and is just pennies away from an all-time high. It's expected to have a solid quarter.
benzinga.com Money Moving Into Healthcare Not AI; Four Fed Presidents Do Not Want a Rate Cut; Euphoria Wearing Off Rotating To Healthcare
benzinga.com Taiwan Semiconductor, HealthEquity, Cboe Global Markets And More: CNBC's 'Final Trades' Stephen Weiss of Short Hills Capital Partners, named Taiwan Semiconductor Manufacturing Company as his final trade.
benzinga.com Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over? Illumina's 23% post-earnings rally revives optimism across biotech ETFs as investors bet on a genomics rebound and ex-China growth in 2025.
benzinga.com Top 6 ETFs To Watch As Wall Street's Strongest Six Months Begin As markets enter their strongest stretch, ETFs tied to AI, banking, and healthcare could shine. Here's where investors are finding fresh momentum.
benzinga.com Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.
benzinga.com SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures.
benzinga.com 4 Biotech Stocks Seeing Explosive Momentum Gains The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to…